Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. (HBIO) covers events occurring on March 6, 2026. The filing details the results of a Special Meeting of Stockholders and the subsequent Board approval of a reverse stock split.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance actions and capital structure changes.
Material Changes
- Stockholder Approval: On March 6, 2026, stockholders approved a proposal to amend the Company's Charter to effect a reverse stock split with a ratio between 1-for-5 and 1-for-15.
- Final Ratio Determination: Following the vote, the Board of Directors selected a final reverse stock split ratio of 1-for-10.
- Share Count Reduction: The number of issued and outstanding shares will decrease from approximately 44,179,894 to approximately 4,471,989.
- Trading Details: The stock is expected to resume trading on a split-adjusted basis on March 16, 2026, under the symbol "HBIO" with a new CUSIP number (416906204).
Outlook, Risks, and Unusual Items
Implementation Timeline: The reverse stock split is effective as of 4:30 p.m. Eastern Time on March 13, 2026. No fractional shares will be issued; instead, fractional interests will be aggregated and sold by the transfer agent, with proceeds distributed in cash to affected stockholders.
Authorized Shares: The authorized number of shares of Common Stock will remain at 80,000,000 following the split.
Regulatory Disclosure: The press release regarding the reverse stock split is provided under Regulation FD but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the new CUSIP number (416906204) for post-split trading.
- Confirm the effective time of the split (March 13, 2026, 4:30 p.m. ET) and the resumption of trading (March 16, 2026).
- Review the mechanism for fractional share cash payments to ensure accurate valuation of holdings.
- Check the definitive proxy statement filed on January 30, 2026, for the full context of the proposals.